Regulatory
Our Quality Commitment
Our team recognizes that every product we manufacture is intended for a patient and that the quality of our work matters to their health. Many of the programs we fill at Argonaut are N=1 personalized therapies, where a single batch represents the only treatment that will be manufactured for a critically ill child. In that context, there is no acceptable failure rate, no tolerable deviation, and no second chance. While these programs represent a small portion of the fills we perform, this reality shapes everything about how we operate: 100% isolator-based filling that removes the human operator as a contamination source, full alignment with EU GMP Annex 1 (2022) including PUPSIT, and 100% in-line non-destructive weight checks that protect every unit of high-value, low-volume product. Most notably, we share a deep sense of responsibility for delivering quality work that our clients and their patients can depend on.
Our founding team brings 40 successful FDA pre-approval inspections (PAIs) from their prior roles. Experience earned batch by batch and applied at Argonaut with the discipline that comes from knowing exactly what is at stake.
We maintain a strong focus on quality, compliance, and continuous improvement across every area of the organization. Our Quality Policy is fundamental to how we operate and is built on four pillars: Personnel Accountability, Self-Initiative, Passion for Excellence, and Trust. These principles guide how our team approaches our work and how we partner with our clients. We work openly and collaboratively with our clients to understand their requirements, manage risk, and ensure quality is built into every stage of their program.
EU Annex 1 Compliance
Argonaut’s sterile fill-finish facilities and processes are designed to meet the requirements of EU GMP Annex 1 for the manufacture of sterile medicinal products. For our clients, this means their programs are built on the most rigorous contamination control standard in the world. Because our isolator-based lines were designed around Annex 1 (2022) from the start, including a formal Contamination Control Strategy and PUPSIT, sponsors can file in the EU and US from a single manufacturing site without remediation risk and support regulatory inspections with a facility that reflects current expectations.
Our approach incorporates advanced aseptic processing technologies, contamination control strategies, and risk-based practices designed to strengthen sterility assurance and support both U.S. and global regulatory requirements.
Contamination Control Strategy
Argonaut maintains a comprehensive contamination control strategy designed to identify, assess, and control contamination risks throughout aseptic manufacturing. Our approach integrates facility and process design, environmental monitoring, cleaning and disinfection, personnel practices, material flows, and aseptic process controls to maintain a state of control.
Isolator-Based Aseptic Processing
Argonaut’s fill-finish operations are 100% isolator-based, providing a highly controlled Grade A environment for aseptic manufacturing.
Isolator technology creates a physical barrier between operators and critical aseptic processing areas, reducing the risk of contamination. Our isolator-based, automated lines support the filling of vials, prefilled syringes, and cartridges across clinical and commercial batch sizes.
This approach aligns with Annex 1’s emphasis on barrier technologies and supports a robust contamination control strategy throughout the filling process.
Pre-Use Post-Sterilization Integrity Testing (PUPSIT)
Argonaut offers Pre-Use Post-Sterilization Integrity Testing (PUPSIT) to support programs requiring alignment with Annex 1 expectations for sterile filtration.
PUPSIT verifies the integrity of a sterilizing-grade filter after sterilization and before it is used for product filtration, providing additional assurance that the filter has not been compromised during sterilization.
Our team works with clients to evaluate filtration requirements and incorporate PUPSIT into the manufacturing process when appropriate for their product and regulatory strategy.
Licenses, Registrations, and ISO Certifications
Argonaut Manufacturing Services is a full-service CDMO providing clinical through commercial fill-finish and supporting services. We maintain multiple licenses, certifications, and registrations to support our clients and their programs.
Argonaut is licensed by the California Food and Drug Branch (FDB) to manufacture both medical devices and drugs at our Carlsbad, California facilities and is ISO 13485 certified by BSI. Links to our licensees, ISO certification and FDA registrations are provided below.
Inspection History & FDA Registrations
Argonaut underwent a PMDA inspection in 2020, and a general FDA inspection in 2022 with no 483 findings. We welcome inspections and audits as an opportunity to demonstrate the strength of our quality systems and commitment to compliance. We’ve successfully completed over 10+ QP inspections and several pre-approval audits from major pharmaceutical companies, with positive outcomes across each inspection.
Argonaut Manufacturing Services maintains current Drug Establishment and Medical Device registrations with the U.S. Food and Drug Administration (FDA). Our FEI number is 3013508066.
Links to our current FDA registrations are provided below.
